Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121071 | 0.87 | HDAC1 (0.59) | POLBTDP1TSHRHDAC1HDAC6 | |
| SCHEMBL28973441 | 0.86 | POLB (0.67) | POLBTDP1TSHRHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL6123175 | 0.86 | HDAC1 (0.57) | POLBTDP1TSHRHDAC1HDAC6 | |
| SCHEMBL18190232 | 0.84 | POLB (0.55) | POLBTDP1TSHRHDAC1HDAC6 | |
| SCHEMBL6121744 | 0.82 | POLB (0.62) | POLBTDP1TSHRHDAC1HDAC6 | |
| SCHEMBL6121791 | 0.82 | POLB (0.62) | POLBTDP1TSHRHDAC1HDAC6 | |
| SCHEMBL6122785 | 0.82 | POLB (0.62) | POLBTDP1TSHRHDAC1HDAC6 | |
| SCHEMBL6122375 | 0.82 | POLB (0.62) | POLBTDP1TSHRHDAC1HDAC6 | |
| SCHEMBL6123067 | 0.82 | POLB (0.62) | POLBTDP1TSHRNPSR1HTT | |
| SCHEMBL6121684 | 0.82 | TRPM8 (0.62) | POLBTDP1TSHRHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | 7 HILLS PHARMA INC. (US) | 2025-01-21 | — | — | US | claimed |
| CN-117980302-A | Piperazine-based agonists of LFA-1 and VLA-4 | 德克萨斯心脏研究所 | 2024-05-03 | — | — | CN | claimed |
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | 7 Hills Pharma LLC (US) | 2022-11-01 | — | — | US | claimed |
| CN-107820429-B | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants | 7山药物有限责任公司 | 2022-08-16 | — | — | CN | claimed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | claimed |
| EP-2881392-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | claimed |
| EP-2640721-B1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | claimed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | claimed |
| EP-4518842-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | 7 HILLS PHARMA INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12109263-B2 | Integrin agonists or activating compounds and methods for making and using same | 7 HILLS PHARMA INC. | 2024-10-08 | — | — | US | disclosed |
| CN-117980302-A | Piperazine-based agonists of LFA-1 and VLA-4 | 德克萨斯心脏研究所 | 2024-05-03 | — | — | CN | disclosed |
| US-20230372253-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3288585-A2 | NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS | 7 HILLS INTERESTS, LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176400-A2 | NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS | 7 HILLS INTERESTS LLC (US) | 2016-11-03 | — | — | WO | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-02-26 | — | — | US | disclosed |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | POLB 3433/4885TDP1 4410/4885TSHR 1793/4885 |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | POLB 3020/4885TDP1 3312/4885TSHR 313/4885 |
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | ITGB7, ITGB1, ITGA1 | POLB 3794/4885TDP1 4383/4885TSHR 943/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | POLB 4323/4885TDP1 4811/4885TSHR 1112/4885 |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | CD47, CD274, ITGB1 | POLB 2213/4885TDP1 4360/4885TSHR 2082/4885 |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | POLB 3246/4885TDP1 3168/4885TSHR 283/4885 |
| US-20230372253-A1 | NOVEL LIPID-BASED SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS CARRIER COMPOSITIONS, INTEGRIN AGONIST ADJUVANT PHARMACEUTICAL COMPOSITIONS THEREFROM, AND METHODS FOR MAKING AND USING SAME | ITGAM, ITGA2, ADGRF1 | POLB 4029/4885TDP1 4732/4885TSHR 433/4885 |
| US-12109263-B2 | Integrin agonists or activating compounds and methods for making and using same | ICOS, CD47, CD274 | POLB 3911/4885TDP1 3886/4885TSHR 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.